COMPOSE: Pivotal phase III trial to compare 177Lu-edotreotide with best standard of care for well-differentiated aggressive grade 2 and grade 3 gastroenteropancreatic neuroendocrine tumours Meeting Abstract
| Authors: | Halfdanarson, T. R.; Halperin, D.; Reidy-Lagunes, D.; Kong, G.; Mailman, J.; Herrmann, K.; Sri Rajaskanthan, R.; Leyden, S.; Capdevila Castillon, J.; Sierras, C.; Harris, P. |
| Abstract Title: | COMPOSE: Pivotal phase III trial to compare 177Lu-edotreotide with best standard of care for well-differentiated aggressive grade 2 and grade 3 gastroenteropancreatic neuroendocrine tumours |
| Meeting Title: | ESMO Congress 2022 |
| Journal Title: | Annals of Oncology |
| Volume: | 33 |
| Issue: | Suppl. 7 |
| Meeting Dates: | 2022 Sep 9-13 |
| Meeting Location: | Paris, France |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2022-09-01 |
| Start Page: | S960 |
| Language: | English |
| ACCESSION: | WOS:000866211601173 |
| DOI: | 10.1016/j.annonc.2022.07.1028 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 902TiP -- Source: Wos |
